Figure 3 | Scientific Reports

Figure 3

From: Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Figure 3

RNA expressions of the genes associated with therapeutic response and improved outcome to anti-PD-1. (a) The RNA expression of the gene CD137 is significantly higher in DCB group compared to NDB group (t-test, P = 2.78e−3) (b). The Kaplan-Meier plots of the patients with high and low RNA expression of each gene indicated that the PFS is higher in the patients with high expressions of CD137, but not statistically significant (log-rank, P = 0.082) (c). The OS does not show statistically significant difference for CD137 (log-rank P = 0.179). (d) The RNA expression of the PSBM9 gene is significantly higher in DCB group compared to NDB group (t-test, P = 6.66e−3).(e). PFS is significantly higher in patients with high PSMB9 RNA expression (log-rank, P = 4.13e−3) (f). OS is similar between two groups (log-rank P = 0.53).

Back to article page